CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Acobiom is developing a non-invasive blood test for pancreatic cancer that utilizes a specific gene signature to improve patient stratification and treatment decisions. This approach aims to enhance personalized medicine in managing this aggressive cancer.
Acobiom is a French Biotech SME (SAS, 8 employees).
Since its foundation, June 1999, Acobiom has always been at the forefront of medical innovation, in particular in biomarker discovery and diagnostic development, thanks to its expertise and knowledge in genomics, transcriptomics, bioinformatics, and data science.
In 2011, Acobiom began working to address the problem of pancreatic cancer.Pancreatic cancer is currently the 4th leading cause of cancer death in Western Countries.
If no action is ta…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
